Search CVSI
CV Sciences, Inc.
OTC · CIK 1510964
Last close0.01
Daily change+0.00 (0.00%)
10 Years gain-96.97%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CVSI · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
46.4Momentum
60.4Acceleration
76.3Confidence
81.0Annual Revenue14
Quarterly Revenue46
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth2.6 / 25
Quality20.3 / 25
Capital Efficiency9.3 / 20
Balance Sheet11.9 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.9469 percentage points.
Operating leverageOperating margin improved by 2.0863 percentage points.
ROIC expansionROIC improved by 11.7033 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 11.3001%.
Key Metrics
Revenue Growth TTM-15.37%OK
Revenue CAGR 3Y-5.24%OK
Gross Margin49.29%OK
Operating Margin-7.85%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-33.08%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y11.3%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $13.79M | $6.75M | -$470,000.00 | -$407,000.00 | -$516,000.00 | 48.97% | -3.41% | -3.74% | -15.29% | 184.26M |
| 2025 FY Dec 31, 2024 | $15.71M | $7.17M | -$2.19M | -$861,000.00 | -$879,000.00 | 45.64% | -13.94% | -5.6% | -96.01% | 175.59M |
| 2024 FY Dec 31, 2023 | $16.00M | $7.09M | $3.36M | $2.25M | $2.25M | 44.27% | 20.99% | 14.08% | 3,387.36% | 153.96M |
| 2023 FY Dec 31, 2022 | $16.21M | $5.55M | -$6.85M | -$1.89M | n/a | 34.25% | -42.25% | n/a | -992.5% | 138.03M |
| 2022 FY Dec 31, 2021 | $20.05M | $8.62M | -$18.45M | -$7.49M | -$7.52M | 42.98% | -92.01% | -37.51% | -219.25% | 107.82M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $13.06M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-349211, 0001193125-25-280515 |
| Revenue Growth TTM | -15.37% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-349211, 0001193125-25-280515 |
| Revenue CAGR 3Y | -5.24% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-126598 |
| Revenue CAGR 5Y | -10.81% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-126598 |
| Gross Profit CAGR 3Y | 6.75% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-126598 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-349211, 0001193125-25-280515 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 49.29% | Gross Profit / Revenue | OK | 0001193125-26-349211, 0001193125-25-280515 |
| Operating Margin | -7.85% | Operating Income / Revenue | OK | 0001193125-26-349211, 0001193125-25-280515 |
| ROIC | -33.08% | NOPAT / Average Invested Capital | OK | 0001193125-26-349211, 0001193125-25-280515 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-349211 |
| Current Ratio | 0.99x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 14.78x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-349211 |
| Revenue per Diluted Share | $0.06 | Revenue / Diluted Shares | OK | 0001193125-26-349211, 0001193125-25-280515 |